Context Therapeutics (NASDAQ:CNTX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Context Therapeutics (NASDAQ:CNTX) from a sell rating to a hold rating in a report issued on Saturday morning.

CNTX has been the subject of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a report on Wednesday, January 21st. JonesTrading initiated coverage on shares of Context Therapeutics in a report on Monday, December 22nd. They set a “buy” rating and a $7.00 target price on the stock. Finally, Lifesci Capital raised shares of Context Therapeutics to a “strong-buy” rating in a research report on Monday, February 23rd. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $6.00.

Context Therapeutics Stock Up 4.9%

Shares of NASDAQ:CNTX opened at $3.02 on Friday. The business’s 50 day moving average is $2.38 and its 200 day moving average is $1.58. The stock has a market cap of $277.48 million, a P/E ratio of -12.58 and a beta of 1.97. Context Therapeutics has a 52-week low of $0.49 and a 52-week high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Monday, March 23rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04). On average, sell-side analysts anticipate that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC bought a new stake in Context Therapeutics during the fourth quarter valued at about $43,000. Quadrature Capital Ltd bought a new position in Context Therapeutics in the fourth quarter worth about $68,000. Clear Harbor Asset Management LLC raised its holdings in Context Therapeutics by 60.5% in the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock worth $90,000 after purchasing an additional 35,000 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Context Therapeutics during the third quarter valued at about $100,000. Finally, XTX Topco Ltd boosted its holdings in shares of Context Therapeutics by 858.8% in the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock valued at $149,000 after buying an additional 91,008 shares in the last quarter. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.